Homepage

Virax Biolabs Group Limited

VRAX NASDAQ Categories PDF
Healthcare · Biotechnology · United Kingdom · Updated May 11, 7:00am
$0.17
Price
$742,474
Market Cap
17
Employees
1.05
Beta
James Foster
CEO
Business Description

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Business History
Price Overview
Last updated: May 11, 2026 1:57pm (just now)
$0.15
-0.02 (-10.70%)
Day Range
$0.15 – $0.19
52-Week Range
$0.10 – $1.20
50-Day MA
$0.17
200-Day MA
$0.43
Volume
9,568,110.00
Analyst Price Targets
Low $1.00
Consensus $1.00
High $1.00
(1 analysts)
Share Structure
Outstanding 4,341,956.00
Float 3,904,056.00
Free Float 89.9%
High free float — 89.9% of shares trade freely, ~10.1% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (3.9M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALC
Stock Price / EPS (Diluted)
-0.09
Stock Price: $0.17
EPS (Diluted): -1.96
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
0.62
Stock Price: $0.17
Total Equity: $5.70M
Shares: 3,103,552
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
0.39
Market Cap: $742,474
Total Debt: $32,468
Cash: $4.23M
EBITDA: -$5.80M
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$-321,232
Market Cap: $742,474
Total Debt: $32,468
Cash: $4.23M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
-838.2%
Gross Profit: -$53,067
Revenue: $6,331
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
-97,344.8%
Operating Income: -$6.16M
Revenue: $6,331
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
-95,739.2%
Net Income: -$6.06M
Revenue: $6,331
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
-102.5%
Net Income: -$6.06M
Total Equity: $5.70M
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
-99.8%
Operating Income: -$6.16M
Tax Rate: 2.2%
Equity: $5.70M
Total Debt: $32,468
Cash: $4.23M
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
7.27
Current Assets: $4.89M
Current Liabilities: $673,207
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.01
Short-Term Debt: $32,468
Long-Term Debt: $0.00
Total Debt: $32,468
Total Equity: $5.70M
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$0.00
Revenue: $6,331
Shares: 3,103,552
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$1.84
Total Equity: $5.70M
Shares: 3,103,552
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$-1.67
Operating CF: -$4.56M
CapEx: -$603,890
Shares: 3,103,552
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.17
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$6.06M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares VRAX against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $123,820 $0 $8,561 $156,419 $6,331
Cost of Revenue $133,254 $0 $9,926 $105,829 $59,398
Gross Profit $-9,434 $0 $-1,365 $50,590 $-53,067
Operating Expenses $635,104 $1.7M $5.7M $6.5M $6.1M
Operating Income $-644,540 -$1.7M -$5.7M -$6.5M -$6.2M
Net Income $-650,984 -$1.7M -$5.5M -$6.7M -$6.1M
EBITDA $0 $-750 -$5.4M -$6.6M -$5.8M
EPS $-0.57 $-1.50 $-5.13 $-3.36 $-1.96
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $17,621 $21,756 $9.4M $3.6M $4.2M
Total Current Assets $39,621 $48,706 $9.6M $4.4M $4.9M
Total Assets $94,118 $48,706 $9.8M $5.5M $6.4M
Current Liabilities $871,435 $1.2M $908,401 $168,849 $673,207
Long-Term Debt $0 $0 $0 $0 $0
Total Liabilities $871,435 $1.2M $908,401 $345,194 $964,750
Total Equity $-596,185 $-974,578 $9.1M $5.4M $5.7M
Retained Earnings -$4.6M -$6.3M -$11.8M -$18.5M -$24.6M
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-590,186 $-809,069 -$4.2M -$6.2M -$4.6M
Capital Expenditure $0 $0 $-178,403 -$1.2M $-603,890
Free Cash Flow $-590,186 $-809,069 -$4.4M -$7.4M -$5.2M
Acquisitions (net) $0 $0 $0 $0 $0
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks $0 $0 $0 $0 $0
Net Change in Cash $-4,988 $4,135 $9.3M -$5.8M $639,700
Analyst Estimates (Annual)
Metric 2024 2025 2026 2027
Revenue $1.4M
$1.4M – $1.4M
 $25,000
$25,000 – $25,000
 $40,000
$40,000 – $40,000
 $4,000
$4,000 – $4,000
EBITDA $-559,999
$-559,999 – $-559,999
 $-9,999
$-9,999 – $-9,999
 $-15,999
$-15,999 – $-15,999
 $-1,599
$-1,599 – $-1,599
Net Income -$5.9M
-$5.9M – -$5.9M
 -$4.6M
-$4.6M – -$4.6M
 -$1.2M
-$1.2M – -$1.2M
 $-744,852
$-744,852 – $-744,852
EPS — — — —
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth -100.0% — +1,727.1% -96.0%
Gross Profit Growth +100.0% — +3,806.2% -204.9%
Operating Income Growth -169.0% -230.7% -13.3% +5.1%
Net Income Growth -162.5% -219.4% -23.4% +10.0%
EBITDA Growth — -725,538.8% -21.4% +12.2%
Insider Trading (Recent)
Date Insider Type Shares Price Value
2026-03-18 HAIGHT NELSON M 2,000.00 $15.40 $30,800
2026-03-18 HAIGHT NELSON M 10,000.00 $6.00 $60,000
2026-03-18 HAIGHT NELSON M 10,000.00 $0.68 $6,800
2026-03-18 HAIGHT NELSON M 10,000.00 $0.88 $8,800
2026-03-18 McCracken Nigel William 20,000.00 $3.60 $72,000
2026-03-18 McCracken Nigel William 50,000.00 $0.68 $34,000
2026-03-18 McCracken Nigel William 29,416.00 $0.88 $25,886
2026-03-18 Foster James Alexander Cunliffe 0.00 $0.00 $0
2026-03-18 Foster James Alexander Cunliffe 37,250.00 $50.00 $1.9M
2026-03-18 Foster James Alexander Cunliffe 40,000.00 $6.00 $240,000
2026-03-18 Foster James Alexander Cunliffe 50,000.00 $0.68 $34,000
2026-03-18 Foster James Alexander Cunliffe 31,975.00 $0.88 $28,138
2026-03-18 Norton Evan Michael 10,000.00 $6.00 $60,000
2026-03-18 Norton Evan Michael 10,000.00 $0.68 $6,800
2026-03-18 Norton Evan Michael 10,000.00 $0.88 $8,800
2026-03-18 Davis Jason 0.00 $0.00 $0
2026-03-18 Miller Iain David 0.00 $0.00 $0
Community AI Feedback
Sign in to Contribute
No community reviews yet for VRAX. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27